Leigh Johnson, NP
Nurse Practitioner · Kingsport, TNNPI 1609861442
Payments from drug & device makers
Across 230 payments — averaging $15.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$566
- Teva Pharmaceuticals USA, Inc.$388
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$347
- Alkermes, Inc.$258
- AbbVie$238
- Lilly USA, LLC$172
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,597100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 45 | $566 |
| Teva Pharmaceuticals USA, Inc. | 31 | $388 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $347 |
| Alkermes, Inc. | 17 | $258 |
| AbbVie | 22 | $238 |
| Lilly USA, LLC | 10 | $172 |
| Exact Sciences | 8 | $164 |
| GSK | 10 | $161 |
| Vanda Pharmaceuticals Inc. | 7 | $144 |
| Bayer | 7 | $127 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $106 |
| Nevro Corp. | 2 | $92 |
| Otsuka America Pharmaceutical, Inc. | 6 | $88 |
| Neurocrine Biosciences, Inc. | 4 | $84 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $65 |
| Inogen, Inc. | 4 | $64 |
| Axsome Therapeutics, Inc. | 3 | $57 |
| AstraZeneca | 3 | $42 |
| Biodelivery Sciences International, Inc. | 3 | $41 |
| Merck | 2 | $38 |
| Si-bone, Inc. | 1 | $38 |
| Lundbeck LLC | 2 | $33 |
| Amgen(2 entities) | 2 | $32 |
| Scilex Pharmaceuticals Inc. | 2 | $30 |
| Indivior Inc. | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Pfizer | 1 | $22 |
| Nalu Medical, Inc. | 2 | $22 |
| Boston Scientific | 1 | $21 |
| Eisai Inc. | 1 | $21 |
| Medtronic | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $10 |
How this compares
$3,597 in reported general payments places this provider in the 85th percentile of 2,662 nurse practitioner providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 44 | $40,547 |
| OzempicSemaglutide | 29 | $37,828 |
| JardianceEmpagliflozin | 32 | $25,767 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $23,528 |
| RybelsusSemaglutide | 17 | $18,123 |
| XareltoRivaroxaban | 16 | $15,470 |
| LinzessLinaclotide | 24 | $13,766 |
| FarxigaDapagliflozin Propanediol | 16 | $13,758 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $7,359 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $2,155 |
| Irbesartan | 19 | $1,428 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 61 | $1,404 |
| Rosuvastatin Calcium | 98 | $1,318 |
| Atorvastatin Calcium | 119 | $1,276 |
| Gabapentin | 114 | $1,083 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $566 | $55,95046 claims |
| PfizerEliquis | $22 | $40,54744 claims |
| GSKTrelegy Ellipta | $161 | $23,52833 claims |
| Johnson & JohnsonXarelto | $16 | $15,47016 claims |
| AbbVieLinzess | $238 | $13,76624 claims |
| AstraZenecaFarxiga | $42 | $13,75816 claims |
| Lilly USA, LLCInsulin Lispro | $172 | $54017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,662 nurse practitioner providers in Tennessee.
Other nurse practitioner in Kingsport
- Cara StoutKingsport$71K
- Autumn HooverKingsport$13K
- Amy HatcherMurfreesboro$1.1M
- Karen RodenKnoxville$265K
- Susan UtleyNashville$194K
- Whitney EricksonMemphis$159K
- Erica HembreeKnoxville$125K
- Brooke FaughtNashville$89K
- Lauren WelchNashville$71K
- S Marie HamiltonOoltewah$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.